All In Biotech

Drug Trial Radar · NCT02908685

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants

A Two Part Seamless, Multi-Center Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy Patients

Last checked: Nov 19, 2026Latest source record: Apr 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 231 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

231

Actual

Start

Oct 19, 2016

Primary completion

Sep 6, 2019

Study completion Oct 2, 2023

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Sep 21, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 2 years, up to 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multi-center, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of Risdiplam in adult and pediatric participants with Type 2 and Type 3 SMA. The study consists of two parts, an exploratory dose finding part (Part 1) of Risdiplam for 12 weeks and a confirmatory part (Part 2) of Risdiplam for 24 months.

Conditions

  • Muscular Atrophy, Spinal

Interventions

  • PlaceboDrug

    Placebo will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).

  • RisdiplamDrug

    Risdiplam will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Selected Part 2 Dose of Risdiplam for Participants With a Body Weight (BW) of >/=20kgTime frame: Day 1 up to at least 4 weeks on study (Up to CCOD of 25 July 2017)
  2. Part 1: Selected Part 2 Dose of Risdiplam for Participants With BW of <20kgTime frame: Day 1 up to at least 4 weeks on study (Up to CCOD of 25 July 2017)
  3. Part 2: Change From Baseline in the Total Motor Function Measure 32 (MFM-32) Total Score at Month 12Time frame: Baseline (Day-1) and Month 12

Locations

45 sites in 16 countries. Site status is shown where the registry gives one.

  • Stanford University Medical Center

    Palo Alto, California

  • Columbia University Medical Center; The Neurological Institute of New York

    New York, New York

  • UZ Gent

    Ghent, Belgium

  • UZ Leuven Gasthuisberg

    Leuven, Belgium

  • Chr de La Citadelle

    Liège, Belgium

  • Instituto de Puericultura E Pediatria Martagão Gesteira

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Alberta Children's Hospital Division of Pediatric Neurology

    Calgary, Alberta, Canada

  • London Health Sciences Centre; Children's Hospital; Pediatrics

    London, Ontario, Canada

  • McGill University Health Centre - Glen Site

    Montreal, Quebec, Canada

  • Peking University First Hospital

    Beijing, China

  • Children's Hospital of Fudan University

    Shanghai, China

  • Clinical Medical Center Zagreb; University Hospital Rebro Department of Paediatrics

    Zagreb, Croatia

  • Hopital Femme Mere Enfant; Medecine Physique et Readaptation Pediatrique ? L?ESCALE

    Bron, France

  • Hopital Roger Salengro

    Lille, France

  • CHU de Nantes - Hotel Dieu

    Nantes, France

  • Hôpital Necker-Enfants Malades; Service de neuropédiatrie

    Paris, France

  • Hopital Armand Trousseau

    Paris, France

  • Universitätsklinikum Freiburg; Klinik für Neuropädiatrie und Muskelerkrankungen

    Freiburg im Breisgau, Germany

  • IRCCS Ospedale Pediatrico Bambino Gesù; U.O. Malattie Neuromuscolari e Neurodegenerative

    Rome, Lazio, Italy

  • Policlinico Agostino Gemelli; Dipartimento di Neuropsichiatria Infantile

    Rome, Lazio, Italy

  • IRCCS Istituto Giannina Gaslini; U.O.S.D. Centro di Miologia e Patologie Neurodegenerative

    Genoa, Liguria, Italy

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Unità Operativa Complessa di Neurologia

    Milan, Lombardy, Italy

  • Fondazione IRCCS Istituto Neurologico ?Carlo Besta?; UO di Neurologia dello Sviluppo

    Milan, Lombardy, Italy

  • Fukuoka Children's Hospital

    Fukuoka, Japan

  • Hiroshima University Hospital

    Hiroshima, Japan

  • Hyogo Medical University Hospital

    Hyōgo, Japan

  • Minami Kyushu National Hospital

    Kagoshima, Japan

  • Miyagi Children's Hospital

    Miyagi, Japan

  • Shiga Medical Center for Children

    Shiga, Japan

  • Shizuoka Children's Hospital

    Shizuoka, Japan

  • Jichi Medical University Hospital

    Tochigi, Japan

  • Center Hospital of the National Center for Global Health and Medicine

    Tokyo, Japan

  • National Center Of Neurology And Psychiatry Hospital

    Tokyo, Japan

  • Szpital Gdanskiego Uniwersytetu Medycznego; Clinic of developmental neurology

    Gda?sk, Poland

  • Uniwersytecki Szpital Kliniczny w Poznaniu; Od. Kliniczny Neurologii Dzieci i M?odziezy

    Późna, Poland

  • Klinika Neurologii I Wydzialu Lekarskiego WUM w Warszawie

    Warsaw, Poland

  • Russian Children Neuromuscular Center of Veltischev

    Moscow, Moscow Oblast, Russia

  • Clinic for Neurology and Psychiatry for Children and Youth

    Belgrade, Serbia

  • Hospital Universitari Vall d'Hebron; Servicio de Reumatologia

    Barcelona, Spain

  • Hospital Universitario La Paz

    Madrid, Spain

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.